Metagenomi Therapeutics, Inc. MGX

Company Overview

Metagenomi, Inc. (NASDAQ: MGX), also referred to publicly as Metagenomi Therapeutics, is a biotechnology company focused on developing next-generation gene editing medicines. The company operates within the gene editing and genomic medicine sectors, with a primary emphasis on discovering and engineering novel genome editing systems derived from naturally occurring microbial diversity. Its platform is designed to support both in vivo and ex vivo therapeutic applications across a range of disease areas, including genetic diseases, immunology, and oncology.

The company’s core business model centers on its proprietary metagenomics-driven discovery platform, which identifies compact and programmable gene editing enzymes beyond conventional CRISPR-Cas systems. Metagenomi aims to differentiate itself through a broad intellectual property portfolio, scalable editing technologies, and potentially improved delivery characteristics for therapeutic use. Founded in 2018 and headquartered in Emeryville, California, the company evolved from advances in metagenomic sequencing and synthetic biology research, later expanding through strategic collaborations and public market financing following its initial public offering in 2024.